Résumé
Germ-cell tumours (GCTs) are the most common type of cancer in young men. Since the late 1970s, disseminated GCT have been a paradigm for curable metastatic cancer and metastatic GCTs are highly curable with cisplatin-based chemotherapy followed by surgical resection of residual masses. Patients' prognosis is currently assessed using the International Germ-Cell Consensus Classification (IGCCC) and used to adapt the burden of chemotherapy. Approximately 20% of patients still do not achieve cure after first-line cisplatin-based chemotherapy, and need salvage chemotherapy (high dose or standard dose chemotherapy). Clinical stage I testicular cancer is the most common presentation and different strategies are proposed: Adjuvant therapies, surgery or surveillance. During the last three decades, clinical trials and strong international collaborations lead to the development of a consensus in the management of GCTs.
Titre traduit de la contribution | Treatment of testicular cancer |
---|---|
langue originale | Français |
Pages (de - à) | 1319-1332 |
Nombre de pages | 14 |
journal | Bulletin du Cancer |
Volume | 100 |
Numéro de publication | 12 |
Les DOIs | |
état | Publié - 1 janv. 2013 |
mots-clés
- Cisplatin
- Germ-cell tumor
- Residual masses
- Testicular cancer